Skip to main content
. 2023 Jan 17;42(5):e110468. doi: 10.15252/embj.2021110468

Figure 3. GSDMD and GSDME are not required for cell death or IL‐1β release upon IAP inhibition.

Figure 3

  • A–C
    BMDMs (5 × 105 cells per well) of the indicated genotypes were primed with 100 ng/ml of LPS for 3 h before treatment with Cp. A (1 μM, up to 16 h as indicated) or nigericin (10 μM) for 20 min, in the absence or presence of the NLRP3 inhibitor MCC950 (5 μM). (A) Cell viability was measured through propidium iodide (PI) uptake and flow cytometry and expressed as a proportion of PI negative (live) cells. (B and C) IL‐1β (B) and TNF (C) levels in cell supernatants were measured by ELISA at the 6 h time point. Data for (A–C) represent the mean of three independent experiments (symbols) and error bars represent the mean ± SD.
  • D
    BMDMS of the indicated genotypes were treated as in A, and cell lysates and supernatants analysed by western blot. Representative of three independent experiments.

Source data are available online for this figure.

HHS Vulnerability Disclosure